BioAge Labs (NASDAQ:BIOA – Get Free Report) and Sol-Gel Technologies (NASDAQ:SLGL – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, valuation, dividends, institutional ownership, earnings, risk and analyst recommendations.
Institutional & Insider Ownership
26.2% of Sol-Gel Technologies shares are owned by institutional investors. 17.6% of BioAge Labs shares are owned by insiders. Comparatively, 66.5% of Sol-Gel Technologies shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Volatility and Risk
BioAge Labs has a beta of 1.19, suggesting that its share price is 19% more volatile than the S&P 500. Comparatively, Sol-Gel Technologies has a beta of 1.25, suggesting that its share price is 25% more volatile than the S&P 500.
Earnings and Valuation
This table compares BioAge Labs and Sol-Gel Technologies”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| BioAge Labs | $8.99 million | 28.37 | -$80.61 million | ($2.55) | -2.18 |
| Sol-Gel Technologies | $19.39 million | 9.30 | -$6.13 million | ($5.23) | -10.54 |
Sol-Gel Technologies has higher revenue and earnings than BioAge Labs. Sol-Gel Technologies is trading at a lower price-to-earnings ratio than BioAge Labs, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares BioAge Labs and Sol-Gel Technologies’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| BioAge Labs | -1,253.60% | -31.42% | -29.59% |
| Sol-Gel Technologies | -1,115.39% | -38.80% | -33.29% |
Analyst Ratings
This is a summary of current recommendations and price targets for BioAge Labs and Sol-Gel Technologies, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| BioAge Labs | 1 | 1 | 6 | 0 | 2.62 |
| Sol-Gel Technologies | 1 | 0 | 4 | 2 | 3.00 |
BioAge Labs presently has a consensus target price of $33.00, suggesting a potential upside of 494.59%. Sol-Gel Technologies has a consensus target price of $197.50, suggesting a potential upside of 258.31%. Given BioAge Labs’ higher probable upside, analysts plainly believe BioAge Labs is more favorable than Sol-Gel Technologies.
Summary
Sol-Gel Technologies beats BioAge Labs on 8 of the 15 factors compared between the two stocks.
About BioAge Labs
BioAge Labs is a clinical-stage biopharmaceutical company developing medicines for metabolic diseases by targeting biological pathways associated with aging. Its research platform draws on human data to identify age-related mechanisms that may be relevant to disease and treatment. The company’s pipeline includes BGE-102, an investigational oral inhibitor of the NLRP3 protein, which is being developed for metabolic conditions. BioAge previously studied azelaprag, an apelin-receptor agonist, but discontinued its development after safety concerns arose in a clinical trial.
About Sol-Gel Technologies
Sol-Gel Technologies is an Israel-based dermatology company that develops topical treatments for skin conditions. Its proprietary technology uses silica-based microencapsulation to formulate active ingredients for topical use. The company’s products include Epsolay, a benzoyl peroxide cream approved in the United States for inflammatory lesions of rosacea, and Twyneo, a topical combination of tretinoin and benzoyl peroxide approved for acne vulgaris. Sol-Gel has pursued commercialization and licensing opportunities in the United States and other markets.
Receive News & Ratings for BioAge Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioAge Labs and related companies with MarketBeat.com's FREE daily email newsletter.
